Stockscreener 앱 받기
2.445
11.09%
-0.305
시간 외 거래:
2.60
0.155
+6.34%
전일 마감가:
$2.75
열려 있는:
$2.73
하루 거래량:
2.45M
Relative Volume:
0.92
시가총액:
$375.50M
수익:
$38.69M
순이익/손실:
$-108.95M
주가수익비율:
-2.00
EPS:
-1.2225
순현금흐름:
$-141.09M
1주 성능:
-10.44%
1개월 성능:
-9.44%
6개월 성능:
-23.59%
1년 성능:
-31.32%
1일 변동 폭
$2.44
$2.73
1주일 범위
$2.44
$2.97
52주 변동 폭
$1.66
$4.33
Editas Medicine Inc Stock (EDIT) Company Profile
명칭
Editas Medicine Inc
전화
617-401-9000
주소
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.445 | 375.50M | 38.69M | -108.95M | -141.09M | -1.2225 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-08 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2026-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2026-08-18 | 개시 | Ladenburg Thalmann | Buy |
| 2025-04-28 | 개시 | H.C. Wainwright | Buy |
| 2024-12-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-13 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-11-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-04 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-05-09 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-10-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-13 | 개시 | Citigroup | Neutral |
| 2022-12-06 | 재개 | Credit Suisse | Neutral |
| 2022-11-18 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-09-29 | 개시 | BofA Securities | Neutral |
| 2021-10-19 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-09-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-08-09 | 업그레이드 | Truist | Hold → Buy |
| 2021-08-05 | 업그레이드 | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | 개시 | Goldman | Sell |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-26 | 다운그레이드 | Truist | Buy → Hold |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | 개시 | Robert W. Baird | Underperform |
| 2020-06-18 | 재개 | SunTrust | Buy |
| 2020-02-21 | 개시 | Wells Fargo | Equal Weight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-10 | 개시 | Guggenheim | Neutral |
| 2018-09-21 | 개시 | Raymond James | Outperform |
| 2018-05-15 | 재확인 | Chardan Capital Markets | Buy |
| 2018-02-13 | 개시 | CLSA | Underperform |
| 2018-01-23 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-07-14 | 개시 | SunTrust | Hold |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-06-02 | 개시 | Jefferies | Hold |
| 2016-02-29 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-29 | 개시 | JP Morgan | Neutral |
| 2016-02-29 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research
Editas Medicine (NasdaqGS:EDIT) Stock Forecast & Analyst Predictions - Simply Wall Street
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy - Yahoo Finance
Opaleye Management Inc. Buys 1,934,933 Shares of Editas Medicine, Inc. $EDIT - MarketBeat
EDIT: EDIT-401 targets up to 90% LDL reduction, with first patient dosing on track for this year - TradingView
Editas Medicine at Cantor conference: in vivo CRISPR push advances - Investing.com
Editas Medicine (NASDAQ: EDIT) Grants 950,000 Derivative Securities to CMO Ory Daniel Scott on September 8, 2026 - Kalkine Media
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Editas Medicine (NASDAQ: EDIT) awards options vesting through 2030 to its CMO - Stock Titan
Editas Medicine (NASDAQ: EDIT) CMO named as reporting insider - Stock Titan
Editas Medicine grants stock options to new chief medical officer - investing.com
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com Australia
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com Nigeria
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com Canada
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com India
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com UK
New medical chief can earn the right to buy 950,000 Editas shares - Stock Titan
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 - MarketBeat
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 - Yahoo Finance
Editas Medicine, Inc. SEC Filing (Sep 9, 2026) - Stock Titan
Editas Medicine Reports Inducement Grants to New Chief Medical Officer - GlobeNewswire
Editas Medicine Reports Inducement Grants to New Chief Medical Officer - Yahoo Finance
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com South Africa
EDIT: EDIT-401 aims for unprecedented LDL reduction, with first human data expected in 2027 - TradingView
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR By Investing.com - Investing.com India
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR - Investing.com
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR - Investing.com UK
Editas Medicine CFO Parison Amy Retains 13,839 Shares After Selling 453 at $3.04 Each - Kalkine Media
Editas Medicine Appoints Dan Ory as Chief Medical Officer - citybiz
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com Nigeria
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com Canada
A potential gene-editing treatment moves toward trials as Editas adds a veteran with more than 25 years' experience. - Stock Titan
Editas Medicine names Dan Ory as chief medical officer - Investing.com
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com UK
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer - GlobeNewswire Inc.
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer - The National Law Review
Seven Fleet Capital Management LP Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Editas Medicine CSO Linda Burkly Sells 709 Shares to Cover RSU Tax Withholding - Kalkine Media
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Shares of Stock - MarketBeat
Editas Medicine CFO Amy Parison Sells Shares in September 2026 Under Pre-Set Plan - kalkinemedia.com
Editas Medicine CEO Gilmore Neil O'Neill Sells 5,124 Shares to Cover Tax Withholding on RSU Vesting - kalkinemedia.com
Editas Medicine (EDIT) CSO stock sale follows tax plan - Stock Titan
Pre-set plan triggers Editas (NASDAQ: EDIT) CFO share sale - Stock Titan
Editas Medicine (NASDAQ: EDIT) CEO sells 5,124 shares in tax-plan trade - Stock Titan
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Editas Medicine (EDIT) Slides 1.3% to $3.04 as Support Level Comes into FocusRetracement Entry - vinanet.vn
Editas Medicine (EDIT) Slides 1.3% to $3.04 as Support Level Comes into FocusGamma Squeeze - siam.in
EditasSlow Progress Doesn't Mean No Progress For In-Vivo Gene Editor (NASDAQ:EDIT) - Seeking Alpha
BlackRock Inc. Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Boston and New York will host Editas Medicine talks this month - stocktitan.net
Editas Medicine Inc (EDIT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Editas Medicine Inc 주식 (EDIT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Parison Amy | SVP, Chief Financial Officer |
Sep 03 '26 |
Sale |
3.04 |
453 |
1,376 |
13,839 |
| O'Neill Gilmore Neil | CEO |
Sep 03 '26 |
Sale |
3.04 |
5,124 |
15,563 |
243,189 |
| O'Neill Gilmore Neil | Officer |
Sep 03 '26 |
Proposed Sale |
3.28 |
5,100 |
16,728 |
0 |
| Burkly Linda | Officer |
Sep 03 '26 |
Proposed Sale |
3.28 |
700 |
2,296 |
0 |
| Parison Amy | SVP, Chief Financial Officer |
Aug 03 '26 |
Sale |
2.58 |
678 |
1,749 |
14,292 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER |
Jul 28 '26 |
Sale |
2.67 |
4,928 |
13,158 |
62,369 |
| Burkly Linda | Officer |
Jul 27 '26 |
Proposed Sale |
2.88 |
5,500 |
15,840 |
0 |
| Parison Amy | SVP, Chief Financial Officer |
Jun 03 '26 |
Sale |
2.70 |
464 |
1,253 |
14,970 |
| O'Neill Gilmore Neil | CEO |
Jun 03 '26 |
Sale |
2.70 |
15,380 |
41,543 |
248,313 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER |
Jun 03 '26 |
Sale |
2.70 |
731 |
1,975 |
67,297 |
4.80%
자본화:
|
볼륨(24시간):